Table 2.
Binary regression of symptomatic infection.
| Variables | Asymptomatic (n = 35) | Symptomatic (n = 133) | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Univariable OR (95%CI) | P | Multivariable OR (95%CI) | P | Multivariable OR (95%CI) | P | ||||
| Gender | Female | 15 (42.9) | 64 (48.1) | 1.00 (Ref.) | |||||
| Male | 20 (57.1) | 69 (51.9) | 1.24 (0.58–2.62) | 0.579 | NA | NA | NA | NA | |
| Age group, y | 0-6 | 14 (40.0) | 64 (48.1) | 1.00(Ref.) | |||||
| >6, ≤12 | 13 (37.1) | 48 (36.1) | 0.81 (0.35–1.88) | 0.619 | NA | NA | NA | NA | |
| >12, <18 | 8 (22.9) | 21 (15.8) | 0.57 (0.21–1.56) | 0.276 | NA | NA | NA | NA | |
| Vaccinationb1 | Unvaccinated | 5 (14.3) | 45 (36.0) | 1.00(Ref.) | |||||
| Vaccinated | 30 (85.7) | 80 (64.0) | 0.30 (0.11–0.82) | 0.019 | NA | NA | NA | NA | |
| Tertiles of IgG | T1(0.01–0.42 S/CO) | 4 (11.4) | 52 (39.1) | 1.00(Ref.) | 1.00(Ref.) | 1.00(Ref.) | |||
| T2(0.43–3.43 S/CO) | 10 (28.6) | 46 (34.6) | 0.35 (0.10–1.21) | 0.097 | 0.19 (0.04-0.82) | 0.026 | 0.19 (0.04-0.83) | 0.028 | |
| T3(3.44–134.32 S/CO) | 21 (60.0) | 35 (26.3) | 0.13 (0.04-0.41) | <0.001 | 0.09 (0.02-0.35) | 0.001 | 0.09 (0.02-0.36) | 0.001 | |
| CRP levels | No. | 35 | 130 | ||||||
| ≤10 mg/L | 34 (97.1) | 117 (90.0) | 1.00(Ref.) | ||||||
| 11–19 mg/L | 0 (0.0) | 7 (5.4) | 469454227.8 (0.00 − +∞) | 0.999 | NA | NA | NA | NA | |
| ≥20 mg/L | 1 (2.9) | 6 (4.6) | 1.74 (0.20–14.99) | 0.612 | NA | NA | NA | NA | |
| PCT levels | No. | 30 | 125 | ||||||
| <0.1 ng/ml | 24 (80.0) | 81 (64.8) | 1.00(Ref.) | ||||||
| 0.1–0.25 ng/ml | 4 (13.3) | 26 (20.8) | 1.93 (0.61–6.06) | 0.263 | NA | NA | NA | NA | |
| >0.25 ng/ml | 2 (6.7) | 18 (14.4) | 2.67 (0.58–12.32) | 0.209 | NA | NA | NA | NA | |
| SAA levels | No. | 29 | 127 | ||||||
| ≤10 μg/ml | 1 (3.4) | 1 (0.8) | 1.00(Ref.) | ||||||
| >10 μg/ml | 28 (96.6) | 126 (99.2) | 4.50 (0.27–74.14) | 0.293 | NA | NA | NA | NA | |
| IL-6 levels | No. | 31 | 125 | ||||||
| ≤7 pg./ml | 26 (83.9) | 95 (76.0) | 1.00(Ref.) | ||||||
| >7 pg./ml | 5 (16.1) | 30 (24.0) | 1.64 (0.58–4.65) | 0.351 | NA | NA | NA | NA | |
| ALT levels | No. | 35 | 132 | ||||||
| ≤40 U/L | 30 (85.7) | 119 (90.2) | 1.00(Ref.) | ||||||
| 41-59 U/L | 3 (8.6) | 8 (6.1) | 0.67 (0.17–2.69) | 0.574 | NA | NA | NA | NA | |
| ≥60 U/L | 2 (5.7) | 5 (3.8) | 0.63 (0.12–3.41) | 0.592 | NA | NA | NA | NA | |
| AST levels | No. | 35 | 133 | ||||||
| ≤40 U/L | 30 (85.7) | 102 (76.7) | 1.00(Ref.) | ||||||
| 41–59 U/L | 2 (5.7) | 19 (14.3) | 2.80 (0.62–12.68) | 0.183 | NA | NA | NA | NA | |
| ≥60 U/L | 3 (8.6) | 12 (9.0) | 1.18 (0.31–4.44) | 0.811 | NA | NA | NA | NA | |
| DDi levels | No. | 34 | 124 | ||||||
| ≤0.50 μg/ml | 27 (79.4) | 94 (75.8) | 1.00(Ref.) | ||||||
| 0.51–0.99 μg/ml | 6 (17.6) | 20 (16.1) | 0.96 (0.35–2.62) | 0.933 | NA | NA | NA | NA | |
| ≥1.00 μg/ml | 1 (2.9) | 10 (8.1) | 2.87 (0.35–23.45) | 0.325 | NA | NA | NA | NA | |
| WBC | No. | 35 | 132 | ||||||
| Mean (SD), 10^9/L | 6.1 (1.9) | 6.0 (2.5) | 0.99 (0.85–1.16) | 0.939 | NA | NA | NA | NA | |
| NEUT | No. | 35 | 132 | ||||||
| Mean (SD), 10^9/L | 2.7 (1.3) | 3.1 (1.7) | 1.15 (0.89–1.48) | 0.274 | NA | NA | NA | NA | |
| LYM | No. | 35 | 132 | ||||||
| Mean (SD), 10^9/L | 2.7 (1.6) | 2.4 (1.9) | 0.90 (0.75–1.09) | 0.294 | NA | NA | NA | NA | |
| Hb | No. | 35 | 132 | ||||||
| Mean (SD), g/L | 129.6 (9.2) | 131.4 (12.1) | 1.01 (0.98–1.05) | 0.401 | NA | NA | NA | NA | |
| PLT | No. | 35 | 132 | ||||||
| Mean (SD), 10^9/L | 247.1 (72.2) | 236.2 (70.4) | 1.00 (0.99–1.00) | 0.418 | NA | NA | NA | NA | |
| FIB | No. | 35 | 128 | ||||||
| Mean (SD), g/L | 2.2 (0.4) | 2.4 (0.6) | 1.79 (0.89–3.60) | 0.101 | 4.18 (1.50–11.63) | 0.006 | 4.15 (1.49–11.59) | 0.007 | |
| N-CT | No. | 28 | 127 | ||||||
| Mean (SD) | 29.1 (4.4) | 27.3 (4.9) | 0.92 (0.84–1.01) | 0.068 | NA | NA | NA | NA | |
| ORF1ab-CT | No. | 26 | 125 | ||||||
| Mean (SD) | 28.9 (5.4) | 27.0 (5.4) | 0.93 (0.86–1.01) | 0.096 | NA | NA | NA | NA | |
| CK | No. | 35 | 131 | ||||||
| Mean (SD), U/L | 84.0 (34.9) | 101.8 (42.7) | 1.01 (1.00–1.02) | 0.027 | NA | NA | NA | NA | |
| CK-MB | No. | 35 | 131 | ||||||
| Mean (SD), U/L | 17.2 (6.0) | 20.3 (9.4) | 1.05 (1.00–1.11) | 0.070 | NA | NA | NA | NA | |
| LDH | No. | 35 | 132 | ||||||
| Mean (SD), U/L | 231.7 (46.7) | 264.9 (70.5) | 1.01 (1.00–1.02) | 0.010 | NA | NA | NA | NA | |
| SARS-CoV-2 IgM | No. | 35 | 133 | ||||||
| Median (IQR), S/CO | 0.2 (0.1, 0.3) | 0.1 (0.1, 0.3) | 0.79 (0.44–1.42) | 0.427 | NA | NA | NA | NA | |
The Spearman correlation coefficient between SARS-CoV-2 IgG antibody level as a continuous variable and vaccine dose was 0.711 (P < 0.001), and that between IgG tertiles and vaccine dose was 0.719 (P < 0.001), so we believe that IgG tertiles can reflect the vaccination status. Furthermore, in univariate regression analysis, the relationship between IgG tertiles and symptomatic infection was more robust than that between vaccine dose and symptomatic infection. Model 2, multivariate regression of IgG tertiles and occurrence of symptomatic infection adjusted for age, gender, vaccination, FIB, N-CT, ORF1ab-CT, CK, CK-MB, and LDH. Model 3, multivariate regression of IgG tertiles and occurrence of symptomatic infection adjusted for age, gender, vaccination, LYM, FIB, N-CT, ORF1ab-CT, CK, CK-MB, LDH. NA, not applicable. b1, the vaccine status of the 8 patients was missing. Missing data were not included in both univariate and multivariate regression.